MX2020003864A - Anticuerpos humanos contra fel d1 y metodos de uso de los mismos. - Google Patents
Anticuerpos humanos contra fel d1 y metodos de uso de los mismos.Info
- Publication number
- MX2020003864A MX2020003864A MX2020003864A MX2020003864A MX2020003864A MX 2020003864 A MX2020003864 A MX 2020003864A MX 2020003864 A MX2020003864 A MX 2020003864A MX 2020003864 A MX2020003864 A MX 2020003864A MX 2020003864 A MX2020003864 A MX 2020003864A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- fel
- allergen
- methods
- basophils
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invención proporciona anticuerpos que unen al alergénico de gato, Fel d1 composiciones que comprenden los anticuerpos, ácidos nucleicos que codifican a los anticuerpos y los métodos de uso de los anticuerpos. De acuerdo con ciertas modalidades de la invención, los anticuerpos son los anticuerpos monoclonales completamente humanos que unen a Fel d1. Los anticuerpos de la invención son útiles para unir al alergénico Fel d1 in vivo previniendo así la unión del alergénico Fel d1 a IgE preformado en la superficie de los mastocitos o de los basófilos. Al hacer esto, los anticuerpos actúan para prevenir la liberación de histamina y otros mediadores inflamatorios de los mastocitos y/o de los basófilos, mejorando así la respuesta inconveniente al alergénico de gato en individuos sensibilizados. Los anticuerpos de la invención también pueden ser útiles para que los propósitos del diagnóstico determinen si un paciente es alérgico al alergénico de gato Fel d1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642083P | 2012-05-03 | 2012-05-03 | |
| US201261718044P | 2012-10-24 | 2012-10-24 | |
| US201361783312P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003864A true MX2020003864A (es) | 2020-08-13 |
Family
ID=48326501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013371A MX377634B (es) | 2012-05-03 | 2013-05-02 | Anticuerpos humanos contra fel d1 y métodos de uso de los mismos. |
| MX2020003864A MX2020003864A (es) | 2012-05-03 | 2014-11-03 | Anticuerpos humanos contra fel d1 y metodos de uso de los mismos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013371A MX377634B (es) | 2012-05-03 | 2013-05-02 | Anticuerpos humanos contra fel d1 y métodos de uso de los mismos. |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US9079948B2 (es) |
| EP (4) | EP2844672B1 (es) |
| JP (2) | JP6400569B2 (es) |
| KR (1) | KR102185516B1 (es) |
| CN (2) | CN104411719B (es) |
| AR (1) | AR090914A1 (es) |
| AU (2) | AU2013256251C1 (es) |
| BR (2) | BR112014026852B1 (es) |
| CA (1) | CA2871077C (es) |
| CY (2) | CY1124023T1 (es) |
| DK (2) | DK3978522T3 (es) |
| ES (3) | ES3049982T3 (es) |
| FI (1) | FI3978522T3 (es) |
| HR (3) | HRP20200652T1 (es) |
| HU (2) | HUE049440T2 (es) |
| IL (1) | IL235121B (es) |
| IN (1) | IN2014DN08767A (es) |
| JO (1) | JO3820B1 (es) |
| LT (3) | LT3978522T (es) |
| MX (2) | MX377634B (es) |
| MY (3) | MY195564A (es) |
| NZ (2) | NZ701124A (es) |
| PL (3) | PL2844672T3 (es) |
| PT (3) | PT3978522T (es) |
| RS (3) | RS67417B1 (es) |
| RU (1) | RU2658491C2 (es) |
| SG (3) | SG10201608378UA (es) |
| SI (3) | SI3660047T1 (es) |
| SM (3) | SMT202500396T1 (es) |
| TW (2) | TWI644921B (es) |
| UY (1) | UY34782A (es) |
| WO (1) | WO2013166236A1 (es) |
| ZA (3) | ZA201407302B (es) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| BR112012000536A2 (pt) | 2009-07-08 | 2020-08-11 | Kymab Limited | métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico |
| BR112014006394A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US10935554B2 (en) | 2013-08-23 | 2021-03-02 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT) |
| DE112014004537T5 (de) | 2013-10-01 | 2016-07-21 | Kymab Limited | Tiermodelle und therapeutische Moleküle |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| RS60739B1 (sr) | 2014-11-17 | 2020-09-30 | Regeneron Pharma | Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela |
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| TW202440904A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（二） |
| AU2016319075B2 (en) * | 2015-09-08 | 2022-09-22 | Universität Zürich | Compositions against cat allergy |
| US12297266B2 (en) | 2016-04-18 | 2025-05-13 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human CD40 and uses thereof |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| HRP20260303T1 (hr) | 2016-12-22 | 2026-04-10 | Regeneron Pharmaceuticals, Inc. | Postupak za liječenje alergije monoklonskim antitijelima specifičnim za alergen |
| MX381157B (es) * | 2017-01-24 | 2025-03-12 | Nestle Sa | Composiciones que comprenden anticuerpos anti-fel d1 y métodos para reducir al menos un síntoma de la alergia humana a los gatos. |
| KR102659791B1 (ko) | 2017-07-06 | 2024-04-23 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| BR112020010615A2 (pt) | 2017-12-22 | 2020-10-27 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema |
| CN111655722A (zh) | 2018-01-31 | 2020-09-11 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| MX2020008988A (es) | 2018-02-28 | 2020-09-28 | Regeneron Pharma | Sistemas y metodos para la identificacion de contaminantes virales. |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CA3089655C (en) | 2018-03-19 | 2026-01-20 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| CN112166119B (zh) * | 2018-05-18 | 2024-12-20 | 陈扎克伯格生物中心旧金山公司 | 从人中分离过敏原特异性抗体的方法及其用途 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| AU2019333047A1 (en) | 2018-08-30 | 2020-12-03 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| ES2942024T3 (es) | 2019-01-16 | 2023-05-29 | Regeneron Pharma | Métodos para caracterizar enlaces disulfuro |
| EP3969908A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| EP4653865A3 (en) | 2019-09-24 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| WO2021108548A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| MX2022008973A (es) | 2020-01-21 | 2022-08-11 | Regeneron Pharma | Metodos de desglicosilacion para electroforesis de proteinas glicosiladas. |
| WO2022046925A1 (en) | 2020-08-26 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| AU2021332355A1 (en) | 2020-08-31 | 2023-03-23 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| WO2022115588A1 (en) | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| JP2024500409A (ja) | 2020-12-17 | 2024-01-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質封入マイクロゲルの作製 |
| KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
| IL305156A (en) | 2021-03-03 | 2023-10-01 | Regeneron Pharma | Systems and methods for quantifying and modifying protein viscosity |
| WO2022192625A1 (en) | 2021-03-11 | 2022-09-15 | IgGenix, Inc. | Methods and systems for predicting allergic response |
| BR112023018665A2 (pt) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | Métodos e sistemas para desenvolvimento de protocolos de mistura |
| EP4348234B1 (en) | 2021-06-01 | 2026-04-08 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
| JP2024531800A (ja) | 2021-09-20 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗体の不均一性を制御する方法 |
| CA3230985A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Ph meter calibration and correction |
| WO2023059800A2 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| CN114113278B (zh) * | 2021-11-24 | 2024-08-02 | 中国计量科学研究院 | 一种基于质谱的体外诊断试剂抗体的表位定位方法 |
| CN118660719A (zh) * | 2021-12-08 | 2024-09-17 | 艾吉尼克斯公司 | 用于过敏症疗法的组合 |
| IL315548A (en) | 2022-03-18 | 2024-11-01 | Regeneron Pharma | Methods and systems for analyzing polypeptide variants |
| AU2023289659A1 (en) | 2022-06-23 | 2024-11-14 | Regeneron Pharmaceuticals, Inc. | Methods of identifying and evaluating cat allergy gene signatures in a subject by determining a stratified score based on gene expression |
| EP4634659A1 (en) | 2022-12-16 | 2025-10-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| US20240255519A1 (en) | 2023-02-01 | 2024-08-01 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| EP4673173A1 (en) | 2023-03-01 | 2026-01-07 | Regeneron Pharmaceuticals, Inc. | Anti-fel d1 antibody formulations |
| WO2024200854A1 (en) | 2023-03-31 | 2024-10-03 | Alk-Abelló A/S | Allergen binding antibodies suitable for treating tree pollen allergies |
| EP4704808A1 (en) | 2023-05-01 | 2026-03-11 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| CN117004650B (zh) * | 2023-06-25 | 2024-05-14 | 山东立菲生物产业有限公司 | 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用 |
| TW202528736A (zh) | 2023-09-08 | 2025-07-16 | 美商再生元醫藥公司 | 用於評估層析管柱完整性的方法及系統 |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| CN121925272A (zh) | 2023-09-29 | 2026-04-24 | 瑞泽恩制药公司 | 利用受控成核进行冻干 |
| CN117069865B (zh) * | 2023-10-12 | 2024-03-01 | 中国农业科学院饲料研究所 | 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备 |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| US20250145662A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| TW202602489A (zh) | 2024-03-15 | 2026-01-16 | 美商再生元醫藥公司 | 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐 |
| CN117964767B (zh) * | 2024-03-29 | 2024-08-06 | 北京恩泽康泰生物科技有限公司 | 抗rage抗体、细胞外囊泡及其制备方法和应用 |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
| WO2026060350A1 (en) | 2024-09-13 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods |
| WO2026076201A2 (en) | 2024-10-03 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools |
| WO2026080597A1 (en) | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5512283A (en) | 1990-07-06 | 1996-04-30 | Allergene, Inc. | Methods for the selective suppression of an immune response to dust mite der Pi |
| CA2128331A1 (en) | 1992-01-21 | 1993-07-22 | Julia L. Greenstein | Methods for using histamine derivatives as immunomodulators and in immunotherapeutics |
| WO1994014475A1 (en) | 1992-12-21 | 1994-07-07 | Tanox Biosystems, Inc. | ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| EP1868642B1 (en) * | 2005-03-18 | 2013-05-08 | Cytos Biotechnology AG | Cat allergen fusion proteins and uses thereof |
| US7566456B2 (en) * | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
| GB0513878D0 (en) * | 2005-07-06 | 2005-08-10 | Mars Inc | Cat allergen |
| WO2007065633A1 (en) | 2005-12-05 | 2007-06-14 | Imvision Ag | Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules |
| WO2007113633A2 (en) * | 2006-04-03 | 2007-10-11 | Pfizer Products Inc. | Immunogenic compositions comprising cat allergen fel dl |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| AT503690A1 (de) | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP1921142A1 (en) * | 2006-11-07 | 2008-05-14 | Cytos Biotechnology AG | Selection of human monoclonal antibodies by eukaryotic cell display |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2008119353A1 (en) * | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| AU2008255352B2 (en) * | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| HUE032078T2 (en) | 2007-07-09 | 2017-08-28 | Nestec Sa | Procedure for reducing allergies caused by environmental allergens |
| BRPI0815370B8 (pt) * | 2007-08-10 | 2021-05-25 | Regeneron Pharma | anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| BR112013008366B1 (pt) | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| US10935554B2 (en) | 2013-08-23 | 2021-03-02 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT) |
| HRP20260303T1 (hr) | 2016-12-22 | 2026-04-10 | Regeneron Pharmaceuticals, Inc. | Postupak za liječenje alergije monoklonskim antitijelima specifičnim za alergen |
-
2013
- 2013-05-01 JO JOP/2013/0131A patent/JO3820B1/ar active
- 2013-05-02 JP JP2015510445A patent/JP6400569B2/ja active Active
- 2013-05-02 PL PL13721544T patent/PL2844672T3/pl unknown
- 2013-05-02 FI FIEP21194412.9T patent/FI3978522T3/fi active
- 2013-05-02 RS RS20251155A patent/RS67417B1/sr unknown
- 2013-05-02 HR HRP20200652TT patent/HRP20200652T1/hr unknown
- 2013-05-02 HR HRP20251429TT patent/HRP20251429T1/hr unknown
- 2013-05-02 EP EP13721544.8A patent/EP2844672B1/en active Active
- 2013-05-02 IN IN8767DEN2014 patent/IN2014DN08767A/en unknown
- 2013-05-02 LT LTEP21194412.9T patent/LT3978522T/lt unknown
- 2013-05-02 MX MX2014013371A patent/MX377634B/es active IP Right Grant
- 2013-05-02 BR BR112014026852-5A patent/BR112014026852B1/pt active IP Right Grant
- 2013-05-02 HU HUE13721544A patent/HUE049440T2/hu unknown
- 2013-05-02 HR HRP20211932TT patent/HRP20211932T1/hr unknown
- 2013-05-02 HU HUE19218187A patent/HUE057062T2/hu unknown
- 2013-05-02 ES ES21194412T patent/ES3049982T3/es active Active
- 2013-05-02 BR BR122019023685-2A patent/BR122019023685B1/pt active IP Right Grant
- 2013-05-02 SG SG10201608378UA patent/SG10201608378UA/en unknown
- 2013-05-02 PT PT211944129T patent/PT3978522T/pt unknown
- 2013-05-02 PT PT192181873T patent/PT3660047T/pt unknown
- 2013-05-02 SI SI201331935T patent/SI3660047T1/sl unknown
- 2013-05-02 TW TW102115645A patent/TWI644921B/zh active
- 2013-05-02 EP EP21194412.9A patent/EP3978522B1/en active Active
- 2013-05-02 PL PL19218187T patent/PL3660047T3/pl unknown
- 2013-05-02 SM SM20250396T patent/SMT202500396T1/it unknown
- 2013-05-02 EP EP19218187.3A patent/EP3660047B1/en active Active
- 2013-05-02 US US13/875,401 patent/US9079948B2/en active Active
- 2013-05-02 MY MYPI2020006733A patent/MY195564A/en unknown
- 2013-05-02 CN CN201380035000.9A patent/CN104411719B/zh active Active
- 2013-05-02 EP EP25194366.8A patent/EP4653056A2/en active Pending
- 2013-05-02 RS RS20200539A patent/RS60282B1/sr unknown
- 2013-05-02 AR ARP130101494 patent/AR090914A1/es unknown
- 2013-05-02 SM SM20220014T patent/SMT202200014T1/it unknown
- 2013-05-02 SG SG10202102919XA patent/SG10202102919XA/en unknown
- 2013-05-02 ES ES13721544T patent/ES2780392T3/es active Active
- 2013-05-02 PT PT137215448T patent/PT2844672T/pt unknown
- 2013-05-02 DK DK21194412.9T patent/DK3978522T3/da active
- 2013-05-02 KR KR1020147033137A patent/KR102185516B1/ko active Active
- 2013-05-02 SI SI201332111T patent/SI3978522T1/sl unknown
- 2013-05-02 MY MYPI2014002857A patent/MY164101A/en unknown
- 2013-05-02 MY MYPI2017701565A patent/MY181422A/en unknown
- 2013-05-02 NZ NZ701124A patent/NZ701124A/en unknown
- 2013-05-02 AU AU2013256251A patent/AU2013256251C1/en active Active
- 2013-05-02 LT LTEP19218187.3T patent/LT3660047T/lt unknown
- 2013-05-02 CN CN201910294004.8A patent/CN110240651B/zh active Active
- 2013-05-02 RS RS20211475A patent/RS62636B1/sr unknown
- 2013-05-02 ES ES19218187T patent/ES2898372T3/es active Active
- 2013-05-02 PL PL21194412.9T patent/PL3978522T3/pl unknown
- 2013-05-02 TW TW106119738A patent/TW201803901A/zh unknown
- 2013-05-02 SG SG11201406748QA patent/SG11201406748QA/en unknown
- 2013-05-02 LT LTEP13721544.8T patent/LT2844672T/lt unknown
- 2013-05-02 RU RU2014148502A patent/RU2658491C2/ru active
- 2013-05-02 SM SM20200241T patent/SMT202000241T1/it unknown
- 2013-05-02 CA CA2871077A patent/CA2871077C/en active Active
- 2013-05-02 DK DK13721544.8T patent/DK2844672T3/da active
- 2013-05-02 NZ NZ733480A patent/NZ733480A/en unknown
- 2013-05-02 WO PCT/US2013/039192 patent/WO2013166236A1/en not_active Ceased
- 2013-05-02 SI SI201331698T patent/SI2844672T1/sl unknown
- 2013-05-03 UY UY34782A patent/UY34782A/es active IP Right Grant
-
2014
- 2014-10-08 ZA ZA2014/07302A patent/ZA201407302B/en unknown
- 2014-10-19 IL IL235121A patent/IL235121B/en active IP Right Grant
- 2014-11-03 MX MX2020003864A patent/MX2020003864A/es unknown
-
2015
- 2015-06-05 US US14/732,578 patent/US9475869B2/en active Active
-
2016
- 2016-09-13 US US15/263,848 patent/US10047152B2/en active Active
-
2017
- 2017-01-26 US US15/416,176 patent/US10047153B2/en active Active
- 2017-06-14 JP JP2017116808A patent/JP6603269B2/ja active Active
-
2018
- 2018-05-03 AU AU2018203087A patent/AU2018203087B9/en active Active
- 2018-07-05 US US16/028,275 patent/US11174305B2/en active Active
-
2020
- 2020-05-04 CY CY20201100408T patent/CY1124023T1/el unknown
- 2020-08-25 ZA ZA2020/05273A patent/ZA202005273B/en unknown
-
2021
- 2021-10-13 US US17/500,418 patent/US12252530B2/en active Active
- 2021-12-20 CY CY20211101115T patent/CY1124819T1/el unknown
-
2022
- 2022-03-09 ZA ZA2022/02846A patent/ZA202202846B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202202846B (en) | Human antibodies to fel d1 and methods of use thereof | |
| PH12019550238A1 (en) | Human antibodies to bet v 1 and methods of use thereof | |
| IL285475A (en) | Anti-blood dendritic cell antigen 2 antibodies and uses thereof | |
| UA104663C2 (xx) | Антитіло, що зв'язує cd127$антитело, связывающее cd127 | |
| UA111340C2 (uk) | Антитіло, яке специфічно зв'язується з tnf-альфа людини | |
| PH12013500564A1 (en) | Anti-cd48 antibodies and uses thereof | |
| MY146664A (en) | Antibodies against human il-22 and uses therefor | |
| EP2558478A4 (en) | AT 5 POSITIONS MODIFIED PYRIMIDINES AND THEIR USE | |
| MY171180A (en) | Anti-hla-b*27 antibodies and uses thereof | |
| EA201590247A1 (ru) | Антитела к siglec-15 | |
| MX345730B (es) | Células adherentes derivadas del amnios (amdac) para usarse en el tratamiento de enfermedades y trastornos relacionados con el sistema inmunitario. | |
| MY162511A (en) | Engineered anti-tslp antibody | |
| UA113609C2 (xx) | Антигензв'язуючий білок, який зв'язує людський il-23 | |
| EA201590209A1 (ru) | Применение cart19 для истощения нормальных b-клеток для индукции толерантности | |
| EA201390660A1 (ru) | Модифицированные никотиновые соединения и связанные способы | |
| JO3547B1 (ar) | أجسام مضادة ضد تخليق جدار الخلية واستعمالاتها | |
| WO2013122544A3 (en) | IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES | |
| BR112013023513A2 (pt) | anticorpos que ligam tgf-alfa e epiregulina | |
| AR117721A2 (es) | Anticuerpos humanos para fel d1 y métodos para usarlos | |
| UA108088C2 (xx) | Сконструйоване антитіло проти tslp | |
| UA113833C2 (xx) | Зв'язуючі il-1 білки |